The Power of Prevention: The Untapped Potential of Adult Immunisation Programmes

By Staff Writer

January 1, 2024

The Unseen Value of Adult Immunisation

Adult immunisation programmes are often overlooked. But these are critical to addressing key health and societal challenges. A detailed review by the  Office of Health Economics (OHE) of these programmes has recently been conducted. Focusing on diseases such as seasonal influenza, pneumococcal disease, herpes zoster, and respiratory syncytial virus, reveals their crucial role in global health. The benefits of these programmes extend beyond health, impacting social care systems and aligning with global agendas such as the UN Sustainable Development Goals (SDGs) and the WHO Immunisation Agenda 2030 (IA2030). However, the full value of such programmes is often underestimated due to underrepresentation in academic literature, leading to suboptimal investment decisions.

The Rising Burden of Infectious Diseases and Ageing Populations

The world is witnessing significant demographic shifts, with ageing populations becoming a dominant trend. Infectious diseases like shingles and pneumococcal disease pose severe threats to older adults, leading to substantial hospitalisation burdens. Alongside this, the ‘tripledemic’ of COVID-19, seasonal influenza, and RSV, coupled with rising rates of chronic diseases among younger age groups, is exerting immense pressure on healthcare systems. This necessitates a shift from treatment to prevention, with vaccination standing as a fundamental preventive measure.

The Economic and Health Benefits of Adult Immunisation

Adult immunisation programmes are not just health measures, but also economically beneficial strategies. They are cost-effective and can result in net cost savings for healthcare systems. Recent studies in Australia and Germany underline that these programmes offer financial gains by averting hospital inpatient and emergency care. Expanding adult immunisation programmes and coverage can lead to substantial productivity gains and economic benefits for society. Moreover, these programmes can contribute to health and economic equity within countries, benefiting vulnerable and underserved communities.

The Urgent Need for Further Research and Adoption of a Preventive Mindset

Despite the clear benefits, significant gaps exist in evidence regarding the broader elements of the value of immunisation programmes. This calls for urgent research to prioritise and enhance adult immunisation programmes for the benefit of society and public health. It is vital for policy- and decision-makers to adopt a prevention-first mindset and implement robust adult immunisation programmes that are proven cost-effective. Expanding the evidence base for the broader value of adult immunisation is a crucial step towards optimising the value of these programmes.

Conclusion: The Power of Prevention

Adult immunisation programmes are powerful tools in the fight against infectious diseases and the burden they place on healthcare systems. They are cost-effective, promote health equity, and align with global health goals. However, their full potential remains untapped, largely due to underrepresentation in academic literature and a lack of awareness among decision-makers. It’s time to shift our focus from treatment to prevention and recognise the immense value that adult immunisation programmes bring to society.

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.